Abstract
A wide range of serum tumor biomarkers, including CA19-9, CA242, CA72-4, CA50, and CA125, has been studied in association with colorectal cancer (CRC). However, few previous studies have comprehensively considered the above tumor biomarkers to assess their clinical significance in predicting prognosis. Data from Fudan University Shanghai Cancer Center (FUSCC) between January 1, 2007 and December 30, 2012 was retrospectively analyzed. Univariate and multivariate analyses were performed to assess the association between prognostic factors and survival outcomes. Nomograms were established based on multivariate Cox regression model analysis for overall survival (OS) and disease free survival (DFS), and c-indexes were 0.772 (95% CI: 0.724-0.820) and 0.715 (95% CI: 0.678–0.752), respectively. Subgroup analyses according to CEA status (high/normal) suggested that CA724 was the only independent prognostic factor for OS (P = 0.001) and DFS (P < 0.001) in the CEA-high group, while, in the CEA-normal group, the only independent prognostic factor for OS (P = 0.031) and DFS (P = 0.043) was CA50. CA50 and CA724 could supplement CEA in monitoring recurrence and metastasis. Accordingly, nomograms based on CEA, CA50, CA724 and other clinical-pathological factors could improve prognosis prediction for colorectal cancer patients.
Highlights
IntroductionThe combination of CEA and CA242 achieved significantly higher sensitivity compared with the use of either biomarker for CRC6
Colorectal cancer (CRC), including CA19-9, CA242, CA72-4, CA50 and CA125
Wang et al demonstrated that the combined analysis of CEA, CA19-9, and CA242 could improve the accuracy of prognostic prediction in surgically treated CRC patients[7]
Summary
The combination of CEA and CA242 achieved significantly higher sensitivity compared with the use of either biomarker for CRC6. Wang et al demonstrated that the combined analysis of CEA, CA19-9, and CA242 could improve the accuracy of prognostic prediction in surgically treated CRC patients[7]. To our knowledge, there is no study in the literature that has comprehensively considered the above tumor biomarkers to evaluate their prognostic value. Nomograms for predicting survival outcomes of CRC with serological tumor markers are scarce. We evaluated the association between preoperative levels of tumor biomarkers and other baseline characteristics and developed nomograms to determine the value of tumor biomarkers for predicting the 5-year survival of patients with CRC who underwent radical resection
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
